Maximum quantity allowed is 999
Please select the quantity
CAS RN: 70024-40-7 | Product Number: T2751
Terazosin Hydrochloride Dihydrate
×
![]()
×
Purity: >98.0%(HPLC)(N)
Synonyms:
- 4-Amino-6,7-dimethoxy-2-[4-(tetrahydro-2-furoyl)-1-piperazinyl]quinazoline Hydrochloride Dihydrate
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 100MG |
₹2,000.00
|
2 | 12 |
|
| 1G |
₹8,300.00
|
2 | 5 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | T2751 |
| Purity / Analysis Method | >98.0%(HPLC)(N) |
| Molecular Formula / Molecular Weight | C__1__9H__2__5N__5O__4·HCl·2H__2O = 459.93 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 70024-40-7 |
| Related CAS RN | 63590-64-7&63074-08-8 |
| Reaxys Registry Number | 6495493 |
| PubChem Substance ID | 125307764 |
| MDL Number | MFCD00941408 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Water | 7.0 to 9.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 274 °C |
GHS
Related Laws:
| RTECS# | TK8046000 |
Transport Information:
Application
Terazosin Hydrochloride: A Long Acting α1-Selective Adrenoceptor Antagonist
Terazosin hydrochloride, a quinazoline derivative, is a long acting α1-selective adrenoceptor antagonist with a similar pharmacodynamic profile to prazosin [P0938]. Terazosin is known to relax vascular and prostate smooth muscle through blockade of α1-adrenoceptors, and lowers blood pressure by decreasing peripheral vascular resistance. In in vitro experiments, terazosin has been shown to contractions in human prostatic tissue, and it is used in the treatment for prostatic hyperplasia (BPH). In addition, some studies indicate that α1-selective adrenoceptor antagonists show suppression of human prostate cancer cell growth. (The product is for research purpose only.)
References
- Adrenergic and serotonergic receptor-blocking potencies of terazosin, a new antihypertensive agent, as assessed by radioligand binding assay
- Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension
- Binding characteristics of naftopidil and α1-adrenoceptor antagonists to prostatic α-adrenoceptors in benign prostatic hypertrophy
- Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis
- Terazosin (The description, physical properties, synthesis, stability, pharmacokinetics, metabolism and analysis of terazosin)
- Validated specific HPLC methods for determination of prazosin, terazosin, and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.